Skip to content

Current ratio at other companies

Guardant Health logo
Guardant HealthGH
4.7×+0.6×
Natera, Inc. logo
Natera, Inc.NTRA
-0.9×
Revvity logo
RevvityRVTY
1.7×-1.9×
Veracyte logo
VeracyteVCYT
9.3×+4.2×
Danaher logo
DanaherDHR
1.9×+0.4×
Charles River Laboratories logo
Charles River LaboratoriesCRL
1.4×-0.1×

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity-0.2×

Where this comes from

Calculated from Adaptive Biotechnologies’s reported figures.

Based on the most recent quarter.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's current ratio?
Adaptive Biotechnologies (ADPT) reported current ratio of 3.4× in Q1 2026.
How has Adaptive Biotechnologies's current ratio changed year-over-year?
Adaptive Biotechnologies's current ratio increased by 14.8% year-over-year, from 2.9× to 3.4×.
What is the long-term trend for Adaptive Biotechnologies's current ratio?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's current ratio has grown at a -13.5% compound annual growth rate (CAGR), from 6.9× to 3.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.